108 related articles for article (PubMed ID: 29781125)
1. Immunoadsorption With a Tryptophan-Immobilized Column Using Conventional and Selective Plasma Separators in the Treatment of Myasthenia Gravis.
Ohkubo A; Kurashima N; Okado T
Ther Apher Dial; 2018 Jun; 22(3):301-302. PubMed ID: 29781125
[No Abstract] [Full Text] [Related]
2. Removal Characteristics of Immunoadsorption with the Tryptophan-Immobilized Column Using Conventional and Selective Plasma Separators in the Treatment of Myasthenia Gravis.
Ohkubo A; Okado T; Sakurasawa T; Maeda T; Itagaki A; Yamamoto H; Miyamoto S; Seshima H; Kurashima N; Mori T; Iimori S; Sohara E; Rai T; Uchida S; Naito S
Ther Apher Dial; 2019 Jun; 23(3):271-278. PubMed ID: 31025833
[TBL] [Abstract][Full Text] [Related]
3. Semi-selective immunoadsorption treatment in myasthenia gravis.
Splendiani G; Passalacqua S; Barbera G; Sturniolo G; Costanzi S; Fulignati P; Casciani CU
Biomater Artif Cells Immobilization Biotechnol; 1992; 20(5):1145-51. PubMed ID: 1457688
[TBL] [Abstract][Full Text] [Related]
4. [In-vitro and in-vivo studies on the selective immunoadsorption treatment of neurological diseases].
Heininger K
Schriftenr Neurol; 1993; 33():1-91. PubMed ID: 8327864
[No Abstract] [Full Text] [Related]
5. [Immunoadsorption--a new treatment of myasthenia gravis].
Berning T; Krummenerl T; Glaser J; Paulus H; van Husen N
Med Klin (Munich); 1988 Feb; 83(4):125-8. PubMed ID: 3285161
[No Abstract] [Full Text] [Related]
6. [Long-term treatment of refractory myasthenia gravis with immunoadsorption].
Wagner S; Janzen RW; Mohs C; Pohlmann S; Klingel R; Grützmacher PW
Dtsch Med Wochenschr; 2008 Nov; 133(46):2377-82. PubMed ID: 18988129
[TBL] [Abstract][Full Text] [Related]
7. Safety, stability, and effectiveness of immunoadsorption under membrane plasmapheresis treatment for myasthenia gravis.
Hosokawa S; Oyamaguchi A
ASAIO Trans; 1990; 36(3):M207-8. PubMed ID: 2252658
[TBL] [Abstract][Full Text] [Related]
8. Immunoadsorption in Guillain-Barré syndrome and myasthenia gravis.
Haupt WF; Rosenow F; van der Ven C; Birkmann C
Ther Apher; 2000 Jun; 4(3):195-7. PubMed ID: 10910018
[TBL] [Abstract][Full Text] [Related]
9. [Immunoadsorption therapy for myasthenia gravis: study on the adsorption capacity of an immunoadsorption column].
Yeh JH; Chiu HC
J Microbiol Immunol Infect; 1999 Jun; 32(2):121-5. PubMed ID: 11565565
[TBL] [Abstract][Full Text] [Related]
10. Changes of plasma proteins after immunoadsorption using Ig-Adsopak columns in patients with myasthenia gravis.
Pták J
Transfus Apher Sci; 2004 Apr; 30(2):125-9. PubMed ID: 15062750
[TBL] [Abstract][Full Text] [Related]
11. The effect of combined therapy with immunoadsorption and high-dose intravenous methylprednisolone on myasthenia gravis.
Munakata R; Utsugisawa K; Nagane Y; Yamagata M; Oikawa M; Obara D; Tohgi H
Eur Neurol; 2002; 48(2):115-7. PubMed ID: 12187003
[No Abstract] [Full Text] [Related]
12. Treatment of severe myasthenia gravis with protein A immunoadsorption and cyclophosphamide.
Flachenecker P; Taleghani BM; Gold R; Grossmann R; Wiebecke D; Toyka KV
Transfus Sci; 1998 Mar; 19 Suppl():43-6. PubMed ID: 10178693
[TBL] [Abstract][Full Text] [Related]
13. Elimination of IgG subclasses of anti-acetylcholine receptor antibodies in myasthenic plasma by immunoadsorption to protein A.
Szpirt W; Somnier F; Nielsen FC; Rødgaard A
Life Support Syst; 1985; 3 Suppl 1():351-5. PubMed ID: 3916613
[No Abstract] [Full Text] [Related]
14. Antigen-specific immunoadsorption of anti-acetylcholine receptor antibodies from sera of patients with myastenia gravis.
Sun C; Meng F; Li Y; Jin Q; Li H; Li F
Artif Cells Blood Substit Immobil Biotechnol; 2010 Apr; 38(2):99-102. PubMed ID: 20196680
[TBL] [Abstract][Full Text] [Related]
15. Extracorporeal whole blood immuno-adsorption of passively transferred myasthenia gravis rabbits by cellulose-tryptophan column.
Li XH; Cheng Y; Yang L; Wang SQ; Yu YT
Artif Cells Blood Substit Immobil Biotechnol; 2010 Aug; 38(4):186-91. PubMed ID: 20380507
[TBL] [Abstract][Full Text] [Related]
16. Treatment of myasthenia gravis with dropped head: a report of 2 cases and review of the literature.
Tamai M; Hashimoto T; Isobe T; Sato H; Doden T; Nakano T
Neuromuscul Disord; 2015 May; 25(5):429-31. PubMed ID: 25747003
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy of immunoadsorption therapy in the treatment of myasthenia gravis and the mechanism].
LI QL; XIE FH; LUO YS
Nan Fang Yi Ke Da Xue Xue Bao; 2011 Mar; 31(3):561-3. PubMed ID: 21421508
[TBL] [Abstract][Full Text] [Related]
18. [The use of therapeutic apheresis in neurological diseases and comparison between plasma exchange and immunoadsorption].
Loschiavo C; Grecò M; Polo A; Del Colle R
G Ital Nefrol; 2015; 32(1):. PubMed ID: 25774587
[TBL] [Abstract][Full Text] [Related]
19. Extracorporeal immunoglobulin elimination for the treatment of severe myasthenia gravis.
Blaha M; Pit'ha J; Blaha V; Lanska M; Maly J; Filip S; Langrova H
J Biomed Biotechnol; 2010; 2010():419520. PubMed ID: 20300435
[TBL] [Abstract][Full Text] [Related]
20. [Plasmapheresis in patients with myasthenia gravis].
Konishi T
Nihon Rinsho; 2008 Jun; 66(6):1165-71. PubMed ID: 18540364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
